Mobile website
Clinical Research
Outcome of patients with recurrent epithelial ovarian carcinoma following treatment with recombinant human adenovirus p53 combined with chemotherapy
- Article
- Figures
- Metrics
- Preview PDF
- Reference
- Related
- Cited by
- Materials
Abstract:
Objective: To evaluate the efficacy of recombinant human adenovirus p53 (rAd-p53) combined with chemotherapy in patients with recurrent epithelial ovarian carcinoma (REOC). Methods: Forty-nine patients with REOC were assigned into a combined-treatment group (n=25) or a mono-chemotherapy group (n=24). Patients in the combined-treatment group underwent chemotherapy plus 2 cycles of rAd-p53 (once a week for 8 weeks), while those in the mono-chemotherapy group received chemotherapy only. Patient outcomes and adverse events were compared between the two groups. Results：The combined-treatment resulted in a significant decrease in CA-125 levels after 3 cycles chemotherapy compared to the monotherapy (P=0.02). There was no significantly difference in the disease control rate (92.0% vs 87.5%, P=0.59), overall survival (39.6 versus 32.5 months, P=0.13) between the two treatment regimens. No serious adverse events were observed in either of the two groups. Conclusion：Patients with REOC may benefit from chemotherapy combined with administration of rAd-p53, without concerns over adverse effects. This benefit needs to be further evaluated in more prospective trials.
Keywords:
Project Supported:
Clc Number:
